BWM
HOWL icon

Baystate Wealth Management’s Werewolf Therapeutics HOWL Stock Holding History

Baystate Wealth Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1.16K Buy
+300
New +$766 ﹤0.01% 1138

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Baystate Wealth Management's HOWL Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Werewolf Therapeutics (HOWL) in Q4 2023: 300 shares worth $1.16K. The stake represents ﹤0.01% of the portfolio and ranks #1138 among its holdings.

41 funds tracked by Wall St. Rank hold HOWL as of Q4 2023.

  • Baystate Wealth Management held 300 shares of Werewolf Therapeutics worth $1.16K as of Q4 2023.
  • Werewolf Therapeutics was a new Baystate Wealth Management position in Q4 2023.
  • Werewolf Therapeutics made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1138 holding.
  • 41 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.